Skip to main content

Advertisement

Table 1 Clinicopathological features of 842 breast cancer patients followed by thyroid cancer and 332,424 breast cancer only patients

From: Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database

 Breast cancer then develop thyroid cacer, n = 842Breast cancer only, n = 332,424p-value
n%n%
Age at diagnosis    < 0.001
 Median age (years)54 [47, 63] 59 [49, 71]  
 ≤ 409511.28%25,7877.76% 
 41–5022026.13%69,21420.82% 
 51–6025730.52%80,75424.29% 
 61–7017220.43%70,47521.20% 
 > 709811.64%86,19425.93% 
Race    0.106
 White66078.39%267,36680.43% 
 Black779.14%30,4699.17% 
 American Indian60.71%22670.68% 
 Asian or Pacific Islander9711.52%30,3119.12% 
 Unknown20.24%20110.60% 
Tumor site    0.912
 Central portion556.53%18,5785.59% 
 Nipple30.37%18890.66% 
 Upper-inner9010.69%34,58010.40% 
 Lower-inner445.22%17,6845.32% 
 Upper-outer30135.75%116,70835.11% 
 Lower-outer566.65%22,5006.77% 
 Overlapping lesion16719.83%68,46020.59% 
 Unknown12614.96%52,03315.65% 
Tumor size    < 0.001
 T ≤ 20 mm50960.45%186,65656.15% 
 21 mm < T ≤ 50 mm23527.91%88,75226.70% 
 T > 50 mm394.63%14,4674.35% 
 Unknown597.01%42,55312.80% 
Positive lymph nodes    0.358
 052662.47%198,44959.70% 
 1–317420.66%71,56021.53% 
 4–9556.53%22,7006.83% 
 ≥ 10273.21%14,5934.38% 
 Unknown607.13%25,1277.56% 
Histology    0.650
 Infiltrating duct carcinoma68981.83%267,86480.57% 
 Lobular carcinoma718.43%29,5708.90% 
 Mixed829.74%34,99310.53% 
Grade    0.351
 113616.15%56,67217.05% 
 235041.57%130,22939.18% 
 328333.61%111,64533.58% 
 4131.54%46361.39% 
 Unknown607.13%29,2478.80% 
ER    0.908
 Positive60171.38%234,14070.43% 
 Negative15518.41%62,34018.76% 
 Borderline20.24%10620.32% 
 Unknown846.41%34,88210.49% 
PR    0.090
 Positive53263.18%197,73759.48% 
 Negative20224.00%92,50927.83% 
 Borderline60.71%20690.62% 
 Unknown10212.11%40,11312.07% 
HER-2    0.061
 Positive131.55%59661.80% 
 Negative455.34%32,1209.66% 
 Unknown78493.11%294,34188.54% 
  1. ER Estrogen receptor, PR Progesterone receptor, HER-2 Human epidermal growth factor receptor 2